Clinical Trial Detail

NCT ID NCT03316794
Title A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications

triple-receptor negative breast cancer

Therapies

SC-005

Age Groups: senior adult

No variant requirements are available.